E7386 has moved into the clinic after an international team reported first-in-human results from a Phase 1, open-label, multicentre trial in advanced cancer. The orally administered regimen is being evaluated for safety, tolerability, pharmacokinetics, and early signals of antitumor activity. The study, published in the British Journal of Cancer in early June 2026, represents an early benchmark for an oral small-molecule approach in settings where sustained dosing and patient convenience can be decisive for adherence and dose intensity. Investigators are using the Phase 1 design to establish dose escalation and identify the next cohort selection steps that will shape future efficacy studies.